Teva (NYSE: TEVA) CFO reports RSU vesting, share exercises and new grant

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive vice president and chief financial officer Eliyahu Sharon Kalif reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised previously granted restricted share units into 33,512 ordinary shares and 23,251 ordinary shares at a price of $0.00 per share, reflecting the settlement of vested awards. The filing also shows a new grant of 53,175 restricted share units, each representing a contingent right to receive one ordinary share or its cash value. Following these transactions, his directly owned ordinary shares increased to 305,519. Footnotes describe multi‑year vesting schedules for the 2022, 2024, and 2026 restricted share unit grants, with installments vesting annually through March 4, 2030, and clarify that ordinary shares may be represented by American Depositary Shares on a one‑to‑one basis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalif Eliyahu Sharon

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/04/2026		M		33,512	A	(2)	282,268	D
Ordinary Shares(1)	03/04/2026		M		23,251	A	(2)	305,519	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/04/2026		M			33,512	(3)	(3)	Ordinary Shares(1)	33,512	$0	0	D
Restricted Share Units	(2)	03/04/2026		M			23,251	(4)	(4)	Ordinary Shares(1)	23,251	$0	46,503	D
Restricted Share Units	(2)	03/04/2026		A		53,175		(5)	(5)	Ordinary Shares(1)	53,175	$0	53,175	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

4. Restricted share units were granted on March 4, 2024, with 23,251 vested on each of March 4, 2025 and March 4, 2026, 23,251 vesting on March 4, 2027, and 23,253 vesting on March 4, 2028.

5. Restricted share units were granted on March 4, 2026, with 13,293 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 13,296 vesting on March 4, 2030.

	/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Teva (TEVA) CFO Eliyahu Sharon Kalif report?

Teva CFO Eliyahu Sharon Kalif reported exercises of vested restricted share units into ordinary shares and a new restricted share unit grant. All reported transactions were acquisitions under equity compensation plans, with no open-market purchases or sales disclosed in this Form 4.

How many restricted share units did Teva (TEVA) CFO have exercised into ordinary shares?

The Form 4 shows 33,512 restricted share units and 23,251 restricted share units exercised into ordinary shares. These exercises occurred on March 4, 2026 at a reported price of $0.00 per share, reflecting settlement of previously granted, vested awards rather than market trades.

What new equity award did Teva (TEVA) CFO receive on March 4, 2026?

On March 4, 2026, the CFO received a grant of 53,175 restricted share units. Each unit represents a contingent right to receive one ordinary share, or at the committee’s option, the cash value of one ordinary share, subject to future vesting conditions over several years.

What is the Teva (TEVA) CFO’s ordinary shareholding after these transactions?

After the reported transactions, the CFO directly owned 305,519 ordinary shares. This total reflects the settlement of vested restricted share units into ordinary shares on March 4, 2026, without any reported dispositions in the filing. Ownership is reported as direct, not through intermediaries.

How do Teva (TEVA) restricted share units granted in 2022 and 2024 vest?

Restricted share units granted March 4, 2022 vest in four equal tranches of 33,512 units each year from 2023 through 2026. Units granted March 4, 2024 vest in four installments: 23,251 units in 2025 and 2026, 23,251 in 2027, and 23,253 in 2028, subject to continued service.

What is the vesting schedule for Teva (TEVA) CFO’s 2026 restricted share unit grant?

The 2026 restricted share unit grant vests over four years. The schedule provides for 13,293 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 13,296 units vesting on March 4, 2030, assuming applicable vesting conditions continue to be met.

How are Teva (TEVA) ordinary shares related to American Depositary Shares in this filing?

The footnotes explain that Teva’s ordinary shares may be represented by American Depositary Shares. Each American Depositary Share currently represents one ordinary share, so reported ordinary share amounts correspond one-to-one with potential ADS holdings for investors accessing the stock via depositary receipts.